Gentian Diagnostics Asa · OSL:GENT
Gentian Diagnostics Asa — Q4 2021 Earnings Presentation
20 slides from Gentian Diagnostics Asa's earnings presentation, Feb 17, 2022
Slide 1: Q4 21 Presentation
Q4 21 Presentation February 17th, 2022
Slide 2: Important notice
Important notice This presentation has been prepared by and is the sole which are subject to risks, uncertainties and other factors with applicable laws and regulations. The Company require responsibility of Gentian Diagnostics ASA (the “Company” that may cause actual events to differ materially fro
Slide 3: Today's presenters
Today’s presenters Hilja Ibert Njaal Kind CEO CFO & COO
Slide 4: Gentian's value proposition
Gentian’s value proposition The growing diagnostic market puts increasing pressure on laboratories. Still, many of the existing, clinically relevant biomarkers are only available on slow and inefficient platforms. By converting biomarkers to the most efficient automated, fast and high-throughput ana
Slide 5: Introduction and highlights
Introduction and highlights
Slide 6: Portfolio of high-impact tests provides solid growth opportunity
Portfolio of high-impact tests provides solid growth opportunity 7* tests contributing Revenue ambition to saving costs and of NOK 1bn in protecting life 5-7 years** Delivered ~27% Industry leading average annual team and knowhow revenue growth 2018-21 * 5 launched, further 2 in development. **Depen
Slide 7: 7 diagnostic tests, including two potential blockbusters
7 diagnostic tests, including two potential blockbusters ESTABLISHED PRODUCTS IN MARKET IN PRODUCT DEVELOPMENT DEVELOPMENT Inflammation Inflammation Kidney disease & infection Inflammation Pancreas & infection Inflammation Cardiac Cystatin C Canine CRP fCAL® fPELA® GCAL® SARS-CoV-2 NT-proBNP 2006 20
Slide 8: Growing into a serviceable market of USD 1.3bn
Growing into a serviceable market of USD 1.3bn Total Addressable Market, USDbn Total Serviceable Market, USDm - growing at 5-6% p.a. - growing at 8-9% p.a. ~1,300 ~800 USD 1,3 7bn+ ~300 ~200 Established GCAL NT-proBNP Serviceable products market Total Addressable Market Market share ambitions ~25% ~
Slide 9: Ambitions for impact, high growth and value creation
Ambitions for impact, high growth and value creation Market opportunity and long-term ambitions Strategic pillars • Grow annual revenue from established products through additional commercial partners and regulatory approvals 5-7 year revenue ambition* NOK 1bn • Prove clinical relevance of GCAL for
Slide 10: Q4 2021 highlights
Q4 2021 highlights • Total operating revenue of NOK 26.2 million, Sales EBITDA up 10% from Q4 2020 NOK 21.7m NOK -8.5m • EBITDA of NOK -8.5 million, of which NOK -4.4 related to +26% vs Q4’20 NOK -7.4m vs Q4’20 implementation of a new ERP system, compared to NOK -1.1 in the corresponding quarter in
Slide 11: NT-proBNP timing remains uncertain
NT-proBNP timing remains uncertain • Revised timeline to be communicated upon completion of the optimization phase • Optimization has been more complex than first assumed • Making progress with particle coating and stability, and showing reproducible results in controlled environment • Remaining cha
Slide 12: Main achievements in 2021
Main achievements in 2021 Sales revenue and growth ▪ Achieved 31% sales growth -and 43% organic sales growth NOK ‘000 - mainly from the established products Cystatin C and fCAL® turbo 90 000 31 % 80 000 ▪ Expansion of commercial footprint including third party sales in 70 000 32 % Norway, Finland an
Slide 13: Financial review
Financial review
Slide 14: Financial highlights
Financial highlights NOKm Q4 2021 Q4 2020 2021 2020 Sales 21.7 17.2 83.1 63.3 Other revenues 4.5 6.6 18.2 15.6 Total revenues 26.2 23.8 101.3 78.9 COGS 10.7 9.1 43.3 32.6 Employee benefit expenses 11.2 8.8 38.4 37.2 D&A 1.0 2.0 7.3 6.6 Other OPEX 12.8 7.0 35.0 20.3 EBITDA -8.5 -1.1 -15.5 -11.2 EBIT
Slide 15: Sales and other revenues
Sales and other revenues Sales - geographic split • Total revenue of NOK 26.2m in the quarter, up 10% vs Q4 20 MNOK 4Q21 4Q20 2021 2020 • 33% growth in organic sales (26% reported) Driven mainly by increased adoption of Cystatin C as a routine marker US 0.5 0.7 2.5 3.0 for chronic kidney disease, an
Slide 16: Operating expenditures in the quarter
Operating expenditures in the quarter NOKm 4Q21 4Q20 2021 2020 Sales and marketing expenses 4.2 4.6 15.2 14.2 Administration expenses 12.9 3.7 32.3 19.4 Research and development 6.9 7.5 25.9 23.9 expenses Total 24.0 15.8 73.4 57.5 24 • High Opex in the quarter, with administration expenses including
Slide 17: Strong cash position; fully financed business plan
Strong cash position; fully financed business plan NOKm Q4 21 Q4 20 2021 2020 Operating activities -15.0 2.6 -28.9 -12.5 Investing activities -1.9 2.2 -12.2 0.3 Financing activities 0.5 0.9 -1.8 -1.5 Changes in cash and cash equivalent -16.4 5.7 -42.9 -13.8 Cash and cash equivalent at the beginning
Slide 18: Summary and outlook
Summary and outlook
Slide 19: Positive portfolio outlook
Positive portfolio outlook ESTABLISHED PRODUCTS GCAL SARS-COV-2 AB NT-proBNP Targeting additional large Increasing endorsements from Successful validation and Continuing work on commercial partners key opinion leaders launch, scheduled for Q1 2022 optimisation Additional regulatory approvals, Streng
Slide 20: Q&A
Q&A